Adopting ICH Q12 and modern technologies can reduce the number of changes that require regulatory approval as well as accelerate evaluation, implementation, and global approval of a change. In a 2017 PDA survey, almost 40% of respondents said that 50% or more of their post-approval changes required submission to a health authority. With increasing complexity in the manufacturing of new therapies and growing number of changes that require filing review and updates in multiple markets, the global post-approval change management (PACM) process is becoming unmanageable.
Modern technologies are reducing complexity in pharma by bringing together systems and people to seamlessly support global, end-to-end processes. With greater visibility and collaboration, change management processes are more efficient and less risky. In this webinar, learn:
Who Will Benefit
Sign Up for FREE Below
Founder and President, Axendia
Daniel R. Matlis, Founder and President, Axendia. Dan’s firm specializes in advising regulated life science and healthcare firms on business, technology and regulatory matters. With 25+ years of experience focusing on the health sciences value chain, he has extensive leadership experience in areas including technology, regulatory compliance, and business. His background includes a B.S. in electrical engineering and an M.S. in technology-focused management.
VP-Vault Quality, Veeva Systems
Mike Jovanis, VP-Vault Quality, Veeva Systems. As Vice President of the Vault Quality product suite, Mike is responsible for product strategy, customer engagement, and business development. Previously, he served as vice president of product management and strategy for Sparta Systems, where he was instrumental in the company's rapid growth, driving product development, vertical market strategy, and strategic partner alliances. Educated at Rutgers, he holds a bachelor’s degree in marketing and an MBA in strategy and global business.